In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
Identifieur interne : 001943 ( Main/Exploration ); précédent : 001942; suivant : 001944In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
Auteurs : RBID : pubmed:21055627English descriptors
- KwdEn :
- Animals, Antibodies, Monoclonal (administration & dosage), Antibodies, Monoclonal (diagnostic use), Antibodies, Monoclonal (immunology), Antibodies, Monoclonal (pharmacokinetics), Apoptosis, Cell Line, Tumor, Cell Transformation, Neoplastic, Female, Humans, Immunohistochemistry, Indium Radioisotopes (diagnostic use), Injections, Lymph Nodes (metabolism), Mice, Ovarian Neoplasms (metabolism), Ovarian Neoplasms (pathology), Ovarian Neoplasms (radiography), Ovarian Neoplasms (radionuclide imaging), Receptor, Epidermal Growth Factor (immunology), Reproducibility of Results, Time Factors, Tomography, Emission-Computed, Single-Photon (methods), Tomography, X-Ray Computed (methods), Vascular Endothelial Growth Factor Receptor-3 (immunology).
- MESH :
- chemical , administration & dosage : Antibodies, Monoclonal.
- chemical , diagnostic use : Antibodies, Monoclonal, Indium Radioisotopes.
- chemical , immunology : Antibodies, Monoclonal, Receptor, Epidermal Growth Factor, Vascular Endothelial Growth Factor Receptor-3.
- chemical , pharmacokinetics : Antibodies, Monoclonal.
- metabolism : Lymph Nodes, Ovarian Neoplasms.
- methods : Tomography, Emission-Computed, Single-Photon, Tomography, X-Ray Computed.
- pathology : Ovarian Neoplasms.
- radiography : Ovarian Neoplasms.
- radionuclide imaging : Ovarian Neoplasms.
- Animals, Apoptosis, Cell Line, Tumor, Cell Transformation, Neoplastic, Female, Humans, Immunohistochemistry, Injections, Mice, Reproducibility of Results, Time Factors.
Abstract
Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 3 (VEGFR-3) are expressed in the tumor area during the progression of ovarian carcinoma. Monoclonal antibodies developed against these receptors are potential diagnostic molecules for in vivo imaging of ovarian carcinoma.
DOI: 10.1016/j.nucmedbio.2010.03.001
PubMed: 21055627
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.</title><author><name sortKey="Huhtala, Tuulia" uniqKey="Huhtala T">Tuulia Huhtala</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biotechnology and Molecular Medicine, University of Eastern Finland, P.O. Box 1627, FIN-70211, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Department of Biotechnology and Molecular Medicine, University of Eastern Finland, P.O. Box 1627, FIN-70211</wicri:regionArea></affiliation></author><author><name sortKey="Laakkonen, Pirjo" uniqKey="Laakkonen P">Pirjo Laakkonen</name></author><author><name sortKey="Sallinen, Hanna" uniqKey="Sallinen H">Hanna Sallinen</name></author><author><name sortKey="Yl Herttuala, Seppo" uniqKey="Yl Herttuala S">Seppo Ylä-Herttuala</name></author><author><name sortKey="N Rv Nen, Ale" uniqKey="N Rv Nen A">Ale Närvänen</name></author></titleStmt><publicationStmt><date when="2010">2010</date><idno type="doi">10.1016/j.nucmedbio.2010.03.001</idno><idno type="RBID">pubmed:21055627</idno><idno type="pmid">21055627</idno><idno type="wicri:Area/Main/Corpus">001718</idno><idno type="wicri:Area/Main/Curation">001718</idno><idno type="wicri:Area/Main/Exploration">001943</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies, Monoclonal (administration & dosage)</term><term>Antibodies, Monoclonal (diagnostic use)</term><term>Antibodies, Monoclonal (immunology)</term><term>Antibodies, Monoclonal (pharmacokinetics)</term><term>Apoptosis</term><term>Cell Line, Tumor</term><term>Cell Transformation, Neoplastic</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>Indium Radioisotopes (diagnostic use)</term><term>Injections</term><term>Lymph Nodes (metabolism)</term><term>Mice</term><term>Ovarian Neoplasms (metabolism)</term><term>Ovarian Neoplasms (pathology)</term><term>Ovarian Neoplasms (radiography)</term><term>Ovarian Neoplasms (radionuclide imaging)</term><term>Receptor, Epidermal Growth Factor (immunology)</term><term>Reproducibility of Results</term><term>Time Factors</term><term>Tomography, Emission-Computed, Single-Photon (methods)</term><term>Tomography, X-Ray Computed (methods)</term><term>Vascular Endothelial Growth Factor Receptor-3 (immunology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Indium Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies, Monoclonal</term><term>Receptor, Epidermal Growth Factor</term><term>Vascular Endothelial Growth Factor Receptor-3</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Antibodies, Monoclonal</term></keywords><keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Lymph Nodes</term><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Tomography, Emission-Computed, Single-Photon</term><term>Tomography, X-Ray Computed</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiography" xml:lang="en"><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Ovarian Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Apoptosis</term><term>Cell Line, Tumor</term><term>Cell Transformation, Neoplastic</term><term>Female</term><term>Humans</term><term>Immunohistochemistry</term><term>Injections</term><term>Mice</term><term>Reproducibility of Results</term><term>Time Factors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 3 (VEGFR-3) are expressed in the tumor area during the progression of ovarian carcinoma. Monoclonal antibodies developed against these receptors are potential diagnostic molecules for in vivo imaging of ovarian carcinoma.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">21055627</PMID><DateCreated><Year>2010</Year><Month>11</Month><Day>08</Day></DateCreated><DateCompleted><Year>2011</Year><Month>02</Month><Day>28</Day></DateCompleted><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1872-9614</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>8</Issue><PubDate><Year>2010</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Nuclear medicine and biology</Title><ISOAbbreviation>Nucl. Med. Biol.</ISOAbbreviation></Journal><ArticleTitle>In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.</ArticleTitle><Pagination><MedlinePgn>957-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.nucmedbio.2010.03.001</ELocationID><Abstract><AbstractText Label="UNLABELLED">Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 3 (VEGFR-3) are expressed in the tumor area during the progression of ovarian carcinoma. Monoclonal antibodies developed against these receptors are potential diagnostic molecules for in vivo imaging of ovarian carcinoma.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Biodistribution of the monoclonal antibodies cetuximab against EGFR and mF4-31C1 against VEGFR-3 was studied in nude mice with orthotopic SKOV-3m human ovarian carcinoma xenografts. The biodistribution of (111)Indium-labeled antibodies was followed up to 48 h postinjection using combined SPECT and CT imaging modality. Organ samples were collected postmortem and specific organ activity was measured. Accumulation of the intravenously injected antibodies in the tumor tissue and lymph nodes was verified using immunohistology.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Imaging studies with SPECT/CT showed clear accumulation of both antibodies into tumor area. The tumor uptake was 8.78 ± 0.74 %ID/g for cetuximab and 5.77 ± 0.62 %ID/g for mF4-31C1 after 48 h postinjection. Cetuximab had lower liver tropism and faster tumor homing rate. In addition, after 48 h two of five tumor-bearing mice showed a clear accumulation of the In-labeled mF4-31C1 at the left axillary area. Both intravenously administered antibodies could also be detected from the tumor sections by immunohistological staining but only mF4-31C1 forms in the lymph nodes.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results demonstrate the accumulation of EGFR- and VEGFR-3-specific antibodies in orthotopic ovarian carcinoma tumors. Systemically administered they had slow pharmacokinetics which is typical for antibodies. Accumulation of mF4-31C1 antibody in the lymph nodes suggests the remote activation of VEGFR-3 by the primary tumor.</AbstractText><CopyrightInformation>Copyright © 2010 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Huhtala</LastName><ForeName>Tuulia</ForeName><Initials>T</Initials><Affiliation>Department of Biotechnology and Molecular Medicine, University of Eastern Finland, P.O. Box 1627, FIN-70211, Finland.</Affiliation></Author><Author ValidYN="Y"><LastName>Laakkonen</LastName><ForeName>Pirjo</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Sallinen</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ylä-Herttuala</LastName><ForeName>Seppo</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Närvänen</LastName><ForeName>Ale</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nucl Med Biol</MedlineTA><NlmUniqueID>9304420</NlmUniqueID><ISSNLinking>0969-8051</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance>Receptor, Epidermal Growth Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance>Vascular Endothelial Growth Factor Receptor-3</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName MajorTopicYN="N">administration & dosage</QualifierName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">immunology</QualifierName><QualifierName MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Apoptosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Cell Transformation, Neoplastic</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Immunohistochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Injections</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Lymph Nodes</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radiography</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptor, Epidermal Growth Factor</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, Emission-Computed, Single-Photon</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName><QualifierName MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Vascular Endothelial Growth Factor Receptor-3</DescriptorName><QualifierName MajorTopicYN="N">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>11</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pii">S0969-8051(10)00058-2</ArticleId><ArticleId IdType="doi">10.1016/j.nucmedbio.2010.03.001</ArticleId><ArticleId IdType="pubmed">21055627</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001943 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001943 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21055627
|texte= In vivo SPECT/CT imaging of human orthotopic ovarian carcinoma xenografts with 111In-labeled monoclonal antibodies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21055627" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |